Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe
Sep 30, 2026, 21:38

John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe

John Kastelein, Co-Founder and Chief Scientific Officer at NewAmsterdam Pharma, Operating Partner of Forbion Capital Management, Chief Executive Officer of Vascular Research Network B.V., Co-Founder of Dezima Pharma and UniQure, shared a post on LinkedIn:

“I recently participated in BioCentury Inc. Grand Rounds Europe in Amsterdam, where I joined colleagues to discuss how advances in vascular biology, genetics, inflammation, thrombosis, and metabolism are changing the way we understand cardiovascular disease.

These mechanisms are deeply interconnected. Understanding why they work the way they do, and how we should scientifically approach them from different points of view, may help inform the next generation of cardiovascular therapies.

That is what makes discussions like this so valuable. Progress requires us to look beyond traditional boundaries, revisit longstanding assumptions, and remain open to where the research and the data lead.

I appreciated the opportunity to learn from my fellow panelists, Peter Carmeliet, Luca Andrea Lotta, and Pieter H. Reitsma, each of whom brought a valuable perspective to the conversation.

Thank you to BioCentury and to our moderator, Vanessa Carle, for bringing us together for such a thoughtful discussion.”

John Kastelein

Stay updated with Hemostasis Today.